Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sinopep-Allsino
Lianyungang, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Sinopep-Allsino is a leading supplier of peptide APIs, especially for metabolic and endocrine indications. Notable programs like semaglutide have reached Phase 3, and several others are in IND or preclinical stages. The company has completed multiple FDA inspections and provides global-standard GMP API manufacturing.
- Therapeutic areas
- EndocrinologyInfectious DiseasesCardiovascularOncologyWomen's Health
- Modalities
- PeptidesSmall moleculeOligonucleotideSynthetic peptide
- Industry
- Biotech
02
Partnerships
Partner and API supplier for global pharma and biotech companiesExclusive API supplier for Albuvirtide and Lanreotide 505b2
Beyond the preview
Go deeper on Sinopep-Allsino.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sinopep-Allsino.